Pharmaceuticals News

Company announcement no. 33 - 2601 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

MELBOURNE, Australia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated...

Ingelheim, Germany, and Bracknell, United Kingdom SCOVELLA® is the first therapy specifically developed and approved for the treatment of hyperinsulinemia in insulin-dysregulated horses and ponies1,...

Resolution Therapeutics partners with the Blood Centers of America to support broad patient access to its experimental Regenerative Macrophage Therapy

COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to...

KØBENHAVN, Danmark, 1. september 2026 – Bavarian Nordic A/S (OMX: BAVA) påbegynder i dag den første del af det nye aktietilbagekøbsprogram, der blev annonceret den 21. august, hvorunder selskabet vil...

Ad hoc announcement pursuant to Art. 53 LR    REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing...

September 1, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in...

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of...

NexLife expands flat-rate compounded GLP-1 care with semaglutide from $119/month and tirzepatide from $139/month, plus microdose and sublingual options.